NASDAQ:PACB

Pacific Biosciences of California Stock Forecast, Price & News

$29.51
+0.29 (+0.99 %)
(As of 06/14/2021 12:00 AM ET)
Add
Compare
Today's Range
$29.24
$30.32
50-Day Range
$22.30
$35.50
52-Week Range
$3.35
$53.69
Volume1.07 million shs
Average Volume3.99 million shs
Market Capitalization$5.85 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.13
30 days | 90 days | 365 days | Advanced Chart
Receive PACB News and Ratings via Email

Sign-up to receive the latest news and ratings for Pacific Biosciences of California and its competitors with MarketBeat's FREE daily newsletter.


Pacific Biosciences of California logo

About Pacific Biosciences of California

Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing systems to resolve genetically complex problems. The company provides PacBio's Systems, which conduct, monitor, and analyse biochemical sequencing reactions; consumable products, including single molecule real-time (SMRT) cells; and various reagent kits designed for specific workflow, such as template preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. The company serves research institutions; commercial laboratories; genome centers; clinical, government, and academic institutions; genomics service providers; pharmaceutical companies; and agricultural companies. It markets its products through a direct sales force in North America and Europe, as well as through distribution partners in Asia, Europe, the Middle East, Africa, and Latin America. Pacific Biosciences of California, Inc. has a collaboration with Invitae Corporation to develop ultra-high-throughput clinical whole genome sequencing platform. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous

Social Links


MarketRank

Overall MarketRank

1.69 out of 5 stars

Medical Sector

324th out of 2,100 stocks

Analytical Instruments Industry

6th out of 32 stocks

Analyst Opinion: 3.4Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Pacific Biosciences of California (NASDAQ:PACB) Frequently Asked Questions

Is Pacific Biosciences of California a buy right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Pacific Biosciences of California in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Pacific Biosciences of California stock.
View analyst ratings for Pacific Biosciences of California
or view top-rated stocks.

What stocks does MarketBeat like better than Pacific Biosciences of California?

Wall Street analysts have given Pacific Biosciences of California a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Pacific Biosciences of California wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Pacific Biosciences of California's next earnings date?

Pacific Biosciences of California is scheduled to release its next quarterly earnings announcement on Monday, August 2nd 2021.
View our earnings forecast for Pacific Biosciences of California
.

How were Pacific Biosciences of California's earnings last quarter?

Pacific Biosciences of California, Inc. (NASDAQ:PACB) posted its earnings results on Thursday, April, 29th. The biotechnology company reported ($0.18) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.45) by $0.27. The biotechnology company earned $29 million during the quarter, compared to analysts' expectations of $25.66 million. Pacific Biosciences of California had a negative net margin of 64.25% and a negative trailing twelve-month return on equity of 43.06%.
View Pacific Biosciences of California's earnings history
.

How has Pacific Biosciences of California's stock been impacted by COVID-19?

Pacific Biosciences of California's stock was trading at $3.44 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, PACB stock has increased by 757.8% and is now trading at $29.51.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for PACB?

4 analysts have issued 1 year price objectives for Pacific Biosciences of California's stock. Their forecasts range from $15.00 to $62.00. On average, they anticipate Pacific Biosciences of California's share price to reach $43.50 in the next twelve months. This suggests a possible upside of 47.4% from the stock's current price.
View analysts' price targets for Pacific Biosciences of California
or view top-rated stocks among Wall Street analysts.

Who are Pacific Biosciences of California's key executives?

Pacific Biosciences of California's management team includes the following people:
  • Mr. Christian O. Henry M.B.A., Pres, CEO & Director (Age 53, Pay $772.45k) (LinkedIn Profile)
  • Ms. Susan G. Kim, Chief Financial Officer (Age 44, Pay $238.87k) (LinkedIn Profile)
  • Dr. Michael W. Hunkapiller, Sr. Fellow & Director (Age 72, Pay $1.17M)
  • Dr. Denis Zaccarin Ph.D., Sr. VP of R&D (Age 56, Pay $440.43k) (LinkedIn Profile)
  • Dr. Stephen Turner, Co-Founder & CTO (Age 53) (LinkedIn Profile)
  • Mr. Mark Van Oene, Chief Operating Officer (Age 48)
  • Ms. Michele Farmer, VP, Chief Accounting Officer & Principal Accounting Officer (Age 42)
  • Dr. Jonas Korlach Ph.D., Chief Scientific Officer
  • Trevin Rard, Head of Investor Relations
  • Brett Atkins J.D., Ph.D., Gen. Counsel & Corp. Sec.

What is Christian Henry's approval rating as Pacific Biosciences of California's CEO?

2 employees have rated Pacific Biosciences of California CEO Christian Henry on Glassdoor.com. Christian Henry has an approval rating of 100% among Pacific Biosciences of California's employees. This puts Christian Henry in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Pacific Biosciences of California's key competitors?

What other stocks do shareholders of Pacific Biosciences of California own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Pacific Biosciences of California investors own include Pfizer (PFE), Gilead Sciences (GILD), Illumina (ILMN), Novavax (NVAX), Advanced Micro Devices (AMD), AT&T (T), Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Invitae (NVTA) and Tesla (TSLA).

What is Pacific Biosciences of California's stock symbol?

Pacific Biosciences of California trades on the NASDAQ under the ticker symbol "PACB."

Who are Pacific Biosciences of California's major shareholders?

Pacific Biosciences of California's stock is owned by a variety of institutional and retail investors. Top institutional investors include ARK Investment Management LLC (10.74%), BlackRock Inc. (8.32%), Jackson Square Partners LLC (6.51%), SB Management Ltd (4.97%), Capital International Investors (4.00%) and Nikko Asset Management Americas Inc. (2.65%). Company insiders that own Pacific Biosciences of California stock include Eric Schaefer, James Michael Phillips, Kathy Ordonez, Lucy Shapiro, Michael Hunkapiller, Susan K Barnes and William W Ericson.
View institutional ownership trends for Pacific Biosciences of California
.

Which institutional investors are selling Pacific Biosciences of California stock?

PACB stock was sold by a variety of institutional investors in the last quarter, including ARK Investment Management LLC, Capital International Investors, Bamco Inc. NY, Viking Global Investors LP, Lord Abbett & CO. LLC, Ameriprise Financial Inc., Jackson Square Partners LLC, and Alyeska Investment Group L.P.. Company insiders that have sold Pacific Biosciences of California company stock in the last year include Eric Schaefer, Kathy Ordonez, Lucy Shapiro, Michael Hunkapiller, and William W Ericson.
View insider buying and selling activity for Pacific Biosciences of California
or view top insider-selling stocks.

Which institutional investors are buying Pacific Biosciences of California stock?

PACB stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Goldman Sachs Group Inc., Renaissance Technologies LLC, Sumitomo Mitsui Trust Holdings Inc., SB Management Ltd, Berkshire Capital Holdings Inc., Nuveen Asset Management LLC, and JPMorgan Chase & Co..
View insider buying and selling activity for Pacific Biosciences of California
or or view top insider-buying stocks.

How do I buy shares of Pacific Biosciences of California?

Shares of PACB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Pacific Biosciences of California's stock price today?

One share of PACB stock can currently be purchased for approximately $29.51.

How much money does Pacific Biosciences of California make?

Pacific Biosciences of California has a market capitalization of $5.85 billion and generates $78.89 million in revenue each year. The biotechnology company earns $29.40 million in net income (profit) each year or ($0.43) on an earnings per share basis.

How many employees does Pacific Biosciences of California have?

Pacific Biosciences of California employs 412 workers across the globe.

When was Pacific Biosciences of California founded?

Pacific Biosciences of California was founded in 2004.

What is Pacific Biosciences of California's official website?

The official website for Pacific Biosciences of California is www.pacb.com.

Where are Pacific Biosciences of California's headquarters?

Pacific Biosciences of California is headquartered at 1305 O`BRIEN DRIVE, MENLO PARK CA, 94025.

How can I contact Pacific Biosciences of California?

Pacific Biosciences of California's mailing address is 1305 O`BRIEN DRIVE, MENLO PARK CA, 94025. The biotechnology company can be reached via phone at 650-521-8000 or via email at [email protected]


This page was last updated on 6/14/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.